Categories Earnings, Health Care

Aethlon Medical (AEMD) Q3 2020 Earnings Snapshot

— Aethlon Medical (NASDAQ: AEMD) reported third quarter 2020 net loss attributable to company of $820,000 or $0.28 per share vs. a loss of $2.1 million $1.67 per share in the prior-year quarter.

— Government contract revenue was $413,458 for the three months ended December 31, 2019.

— Operating expenses were $1.29 million compared to $1.96 million in the three months ended December 31, 2018.

— Aethlon announced that SEC had temporarily suspended trading of the company stock for a period of ten days.

— Aethlon clarified that its proprietary blood filtration cartridge Hemopurifier, which is in the development stage, would not be an initial front line treatment for the 2019-nCoV virus.

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top